Image-guided robotic radiosurgery as salvage therapy for locally recurrent prostate cancer after external beam irradiation: Retrospective feasibility study on six cases

Tumori

Volumn 96, Issue 1, 2010, Pages 71-75

  Vavassori, Andrea ^a   Jereczek Fossa, Barbara Alicja ^a,c   Beltramo, Giancarlo ^b   De Cicco, Luigi ^a   Fariselli, Laura ^d   Bianchi, Livia Corinna ^b   Possanzini, Marco ^b   Bergantin, Achille ^b   DeCobelli, Ottavio ^a,c   Orecchia, Roberto ^a,c  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b Centro Diagnostico Italiano   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d DEPARTMENT OF NEUROSURGERY   (Italy)

Author keywords

CyberKnife; Prostate cancer; Reirradiation; Salvage therapy

Indexed keywords

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BIOCHEMISTRY; CANCER RECURRENCE; CLINICAL ARTICLE; CYBERKNIFE; EXTERNAL BEAM RADIOTHERAPY; FEASIBILITY STUDY; FOLLOW UP; HUMAN; IMAGE GUIDED ROBOTIC RADIOSURGERY; LOCALLY RECURRENT PROSTATE CANCER; MALE; PROSTATE CANCER; RADIATION DOSE FRACTIONATION; RECURRENT CANCER; RETROSPECTIVE STUDY; SAFETY; SALVAGE THERAPY; TOXICITY;

AGED; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; FEASIBILITY STUDIES; FOLLOW-UP STUDIES; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOSURGERY; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RETREATMENT; RETROSPECTIVE STUDIES; ROBOTICS; SALVAGE THERAPY; SAMPLE SIZE; TREATMENT OUTCOME;

EID: 77950793999     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089161009600112     Document Type: Article

References (41)

1. Inghelmann R, Grande E, Francisci S,Verdecchia A,Micheli A, Baili P, Gatta G, Capocaccia R,Valdagni R, De Angelis R: Regional estimates of prostate cancer burden in Italy. Tumori, 93: 380-386, 2007. (Pubitemid 47403454)
2. Ward JF, Moul JW: Biochemical recurrence after definitive prostate cancer therapy. Part I: defining and localizing biochemical recurrence of prostate cancer. Curr OpinUrol, 15: 181-186, 2005.
3. Jereczek-Fossa BJ, Orecchia R: Evidence-based radiation oncology: definitive, adjuvant and salvage radiotherapy for non-metastatic prostate cancer. Radiother Oncol, 84: 197-215, 2007.
4. Heidenreich A, Aus G, Bolla M, Joniau S, Matveev VB, Schmid HP, Zattoni F: EAU Guidelines on prostate cancer. Eur Urol, 53: 68-80, 2008.
5. Schwarz R, GraefenM, Krull A:Therapy of treatment failure after curative treatment of prostate cancer. EAU-EBU Update Series, 4: 228-240, 2006.
6. de Jong IJ, Pruim J, Elsinga PH, Vaalburg W, Mensink HJ: 11C-choline positron emission tomography for the evaluation after treatment of localized prostate cancer. Eur Urol, 44: 32-38, 2003.
7. Pucar D, Sella T, Schöder H: The role of imaging in the detection of prostate cancer local recurrence after radiation therapy and surgery. Curr Opin Urol, 18: 87-97, 2008.
8. Touma NJ, Izawa JI, Chin JL: Current status of local salvage therapies following radiation failure for prostate cancer. J Urol, 173: 373-379, 2005.
9. D'Amico AV, Moul JW, Carroll PR, Sun L, Lubeck D, Chen MH: Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst, 95: 1376-1383, 2003.
10. Spiess PE, Lee AK, Leibovici D, Wang X, Do KA, Pisters LL: Presalvage prostate-specific antigen (PSA) and PSA doubling time as predictors of biochemical failure of salvage cryotherapy in patients with locally recurrent prostate cancer after radiotherapy. Cancer, 107: 275-280, 2006.
11. Sartor CI, Strawderman MH, Lin XH, Kish KE, McLaughlin PW, SandlerHM: Rate of PSA rise predictsmetastatic versus local recurrence after definitive radiotherapy. Int J Radiat Oncol Biol Phys, 38: 941-947, 1997.
12. Sengupta S, Amling C, D'Amico AV, BluteML: Prostate specific antigen kinetics in the management of prostate cancer. J Urol, 179: 821-826, 2008.
13. Lee AK, Levy LB, Cheung R, Kuban D: Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy. Int J Radiat Oncol Biol Phys, 63: 456-462, 2005.
14. Gillatt D, Keane T,Miller K : Preface. Eur Urol Suppl, 6: 325-326, 2007.
15. Keane T, Gillat D, Lawton C, Payne H, Tombal B: Treatment options in prostate cancer once primary therapy fails. Eur Urol Suppl, 6: 344-353, 2007.
16. Nguyen PL, D'Amico AV, Lee AK, Suh WW: Patient selection, cancer control, and complications after salvage local therapy for postradiation prostate-specific antigen failure: a systematic review of the literature. Cancer, 110: 1417-1428, 2007.
17. Andrews DW, Bednarz G, Evans JJ, Downes B: A review of 3 current radiosurgery systems. Surgical Neurology, 66: 559-564, 2006.
18. Bondiau PY, Bénézery K, BeckendorfV, PeiffertD, Gérard JP, Mirabel X, Noël A, Marchesi V, Lacornerie T, Dubus F, Sarrazin T, Herault J, Marcié S, Angellier G, Lartigau E: CyberKnife robotic stereotactic radiotherapy: technical aspects and medical indications. Cancer Radiother, 11: 338-344, 2007.
19. Prostate cancer. In: National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology, version 1.2008. Jenkinstown, PA: National Comprehensive Cancer Network, March 2008 (Available at http://www.nccn.org/ professionals/physician-gls/default.asp accessed February 2010).
20. Roach M III, Hanks G, Thames H Jr, Schellhammer P, Shipley WU, Sokol GH, Sandler H: Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys, 65: 965-974, 2006.
21. Prostate Cancer Nomograms. Available at http://www. mskcc.org/ applications/nomograms/prostate/PsaDoublingTime. aspx (accessed February 2010).
22. Joiner MC, Bentzen SM: Time-dose relationships: the linear- quadratic approach. In: Basic clinical radiobiology, 3rd ed, Steel GG (Ed), pp 120-133, Arnold, London 2002.
23. Brenner DJ, Martinez AA, Edmundson GK, Mitchell C, Thames HD, Armour EP: Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue. Int J Radiat Oncol Biol Phys, 52: 6-13, 2002.
24. Fowler J, Chappell R, Ritter M: Is alpha/beta for prostate tumors really low? Int J Radiat Oncol Biol Phys, 50: 1021-1031, 2001.
25. Dasu A: Is the α/βvalue for prostate tumours low enough to be safely used in clinical trials? Clin Oncol (R Coll Radiol), 19: 289-301, 2007.
26. Wang JZ, Guerrero M, Li XA: How low is the α/βratio for prostate cancer? Int J Radiat Oncol Biol Phys, 55: 194-203, 2003.
27. Cox JD, Stetz J, Pajak TF: Toxicity criteria of the Radiation Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys, 31: 1341-1346, 1995.
28. Bianco FJ, Scardino PT, Stephenson AJ, DiBlasio CJ, Fearn PA, Eastham BA: Long-term oncologic results of salvage radical prostatectomy for locally recurrent prostate cancer after radiotherapy. Int J Radiat Oncol Biol Phys, 62: 448-453, 2005.
29. Allen GW, Howard AR, Jarrad DF, Ritter MA: Management of prostate cancer recurrences after radiation therapy - Brachytherapy as a salvage option. Cancer, 110: 1405-1416, 2007.
30. Ng CK, Moussa M, Downey DB, Chin JL: Salvage cryoablation of the prostate: follow up and analysis of predictive factors for outcome. J Urol, 178: 1253-1257, 2007.
31. Gelet A, Chapelon JY, Poissonnier L, Bouvier R, Rouvière O, Curiel L, Janier M, Vallancien G: Local recurrence of prostate cancer after external beamradiotherapy: early experience of salvage therapy using high-intensity focused ultrasonography. Urology, 63: 625-629, 2004.
32. TharpM, HardacreM, Bennett R, JonesWT, Stuhldreher D, Vaught J: Prostate high-dose-rate brachytherapy as salvage treatment of local failure after previous external or permanent seed irradiation for prostate cancer. Brachytherapy, 7: 231-236, 2008.
33. Lotan Y, Stanfield J, Cho LC, Sherwood JB, Abdel-Aziz KF, Chang CH, Forster K, Kabbani W, Hsieh JT, Choy H, Timmerman R: Efficacy of high dose per fraction radiation for implanted human prostate cancer in a nude mouse model. J Urol, 175: 1932-1936, 2006.
34. Grills IS, Martinez AA, Hollander M, Huang R, Goldman K, Chen PY, Gustafson GS: High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladiumseeds. J Urol, 171: 1098-1104, 2004.
35. Kupelian PA, Reddy CA, Klein EA, Willoughby TR: Shortcourse intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: preliminary results on late toxicity and quality of life. Int J Radiat Oncol Biol Phys, 51: 988-993, 2001.
36. Fowler JF, Nahum AE, Orton CG: Point/Counterpoint. The best radiotherapy for the treatment of prostate cancer involves hypofractionation. Med Phys, 33: 3081-3084, 2006.
37. Madsen BL, Hsi RA, Pham HT, Fowler JF, Esagui L, Corman J: Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: first clinical trial results. Int J Radiat Oncol Biol Phys, 67: 1099-1105, 2007.
38. King CR, Lehmann J, Brooks JD, Grill H, Pawlicki T, Cotrutz C, Presti JC: Stereotactic body radiotherapy for localized prostate cancer: interim results of a prospective phase II clinical trial. Int J Radiat Oncol Biol Phys, 73: 1043-1048, 2009.
39. Pawlicki T, Cotrutz C, King C: Prostate cancer therapy with stereotactic body radiation therapy. Front Radiat Ther Oncol, 40: 395-406, 2007.
40. Hannoun-Levi JM, Benezery K, Bondiau PY, Chamorey E, Marcié S, Gerard JP: Robotic radiotherapy for prostate cancer with CyberKnife. Cancer Radiother, 11: 476-482, 2007.
41. Fuller DB, Naitoh J, Lee C, Steven H, Jin H: Virtual HDR CyberKnife treatment for localized prostatic carcinoma: dosimetry comparison with HDR brachytherapy and preliminary clinical observations. Int J Radiat Oncol Biol Phys, 70: 1588-1597, 2008.